Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Nov;63(11):4261–4267. doi: 10.1128/iai.63.11.4261-4267.1995

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

E Handman 1, F M Symons 1, T M Baldwin 1, J M Curtis 1, J P Scheerlinck 1
PMCID: PMC173605  PMID: 7591056

Abstract

Leishmania major promastigote surface antigen-2 complex (PSA-2) comprises a family of three similar but distinct polypeptides. The three PSA-2 polypeptides were purified from cultured promastigotes by a combination of detergent phase separation and monoclonal antibody affinity chromatography. Intraperitoneal vaccination of C3H/He mice with PSA-2 with Corynebacterium parvum as an adjuvant resulted in complete protection from lesion development after challenge infection with virulent L. major. Significant protection was also obtained in the genetically susceptible BALB/cH-2k and BALB/c mice. One of the PSA-2 genes was cloned and expressed in both Escherichia coli and Leishmania mexicana promastigotes. Vaccination with the recombinant PSA-2 purified from E. coli did not confer protection, in contrast to the L. mexicana-derived recombinant PSA-2, which provided excellent protection. CD4+ T cells isolated from the spleens of vaccinated mice produced large amounts of gamma interferon but no detectable interleukin 4 upon stimulation with PSA-2 in vitro. Limiting dilution analysis showed a marked increase in the precursor frequency of PSA-2-specific gamma interferon-secreting CD4+ T cells. No substantial change in precursor frequency was observed for interleukin 4-secreting T cells in the vaccinated mice. A CD4+ PSA-2 specific T-cell line generated from splenocytes of a vaccinated mouse produces a cytokine pattern consistent with a TH1 phenotype. Intravenous injection of this line into naive mice reduced significantly the parasite burden upon challenge infection. Taken together, the data suggest that vaccination with PSA-2 induces a TH1 type of immune response which protects mice from L. major infection. Moreover, a single recombinant PSA-2 polypeptide derived from a genomic clone can also vaccinate, provided that the structural form of the antigen is near native.

Full Text

The Full Text of this article is available as a PDF (380.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebischer T., Moody S. F., Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun. 1993 Jan;61(1):220–226. doi: 10.1128/iai.61.1.220-226.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bogdan C., Gessner A., Röllinghoff M. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology. 1993 Nov;189(3-4):356–396. doi: 10.1016/S0171-2985(11)80366-9. [DOI] [PubMed] [Google Scholar]
  3. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem. 1981 Feb 25;256(4):1604–1607. [PubMed] [Google Scholar]
  4. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun. 1988 Dec;56(12):3272–3279. doi: 10.1128/iai.56.12.3272-3279.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheever M. A., Thompson D. B., Klarnet J. P., Greenberg P. D. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med. 1986 May 1;163(5):1100–1112. doi: 10.1084/jem.163.5.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cruz A., Beverley S. M. Gene replacement in parasitic protozoa. Nature. 1990 Nov 8;348(6297):171–173. doi: 10.1038/348171a0. [DOI] [PubMed] [Google Scholar]
  7. Greenblatt C. L. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res. 1980;47:259–285. [PubMed] [Google Scholar]
  8. Groves P. L., Pech M. H., Troutt A. B., Kelso A. Limiting dilution analysis reveals the precursors of interleukin-4-producing CD4+ cells induced by protein immunization. Immunology. 1994 Sep;83(1):25–32. [PMC free article] [PubMed] [Google Scholar]
  9. Hager D. A., Burgess R. R. Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes. Anal Biochem. 1980 Nov 15;109(1):76–86. doi: 10.1016/0003-2697(80)90013-5. [DOI] [PubMed] [Google Scholar]
  10. Handman E., Ceredig R., Mitchell G. F. Murine cutaneous leishmaniasis: disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages. Aust J Exp Biol Med Sci. 1979 Feb;57(1):9–29. doi: 10.1038/icb.1979.2. [DOI] [PubMed] [Google Scholar]
  11. Handman E., Hocking R. E., Mitchell G. F., Spithill T. W. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol. 1983 Feb;7(2):111–126. doi: 10.1016/0166-6851(83)90039-7. [DOI] [PubMed] [Google Scholar]
  12. Handman E., Mitchell G. F. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5910–5914. doi: 10.1073/pnas.82.17.5910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jaffe C. L., Rachamim N., Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol. 1990 Jan 15;144(2):699–706. [PubMed] [Google Scholar]
  14. Jardim A., Alexander J., Teh H. S., Ou D., Olafson R. W. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med. 1990 Aug 1;172(2):645–648. doi: 10.1084/jem.172.2.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kahl L. P., McMahon-Pratt D. Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein. J Immunol. 1987 Mar 1;138(5):1587–1595. [PubMed] [Google Scholar]
  16. Kelso A. Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction. J Immunol. 1990 Oct 1;145(7):2167–2176. [PubMed] [Google Scholar]
  17. LeBowitz J. H., Coburn C. M., McMahon-Pratt D., Beverley S. M. Development of a stable Leishmania expression vector and application to the study of parasite surface antigen genes. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9736–9740. doi: 10.1073/pnas.87.24.9736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lohman K. L., Langer P. J., McMahon-Pratt D. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8393–8397. doi: 10.1073/pnas.87.21.8393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Luft B. J., Castro K. G. An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):178–181. doi: 10.1007/BF01964455. [DOI] [PubMed] [Google Scholar]
  20. McMahon-Pratt D., Rodriguez D., Rodriguez J. R., Zhang Y., Manson K., Bergman C., Rivas L., Rodriguez J. F., Lohman K. L., Ruddle N. H. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun. 1993 Aug;61(8):3351–3359. doi: 10.1128/iai.61.8.3351-3359.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McMahon-Pratt D., Traub-Cseko Y., Lohman K. L., Rogers D. D., Beverley S. M. Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex. Mol Biochem Parasitol. 1992 Jan;50(1):151–160. doi: 10.1016/0166-6851(92)90252-f. [DOI] [PubMed] [Google Scholar]
  22. Mitchell G. F., Handman E., Spithill T. W. Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major. Int J Parasitol. 1985 Dec;15(6):677–684. doi: 10.1016/0020-7519(85)90015-3. [DOI] [PubMed] [Google Scholar]
  23. Modabber F. A model for the mechanism of sensitivity of BALB/c mice to L. major and premunition in leishmaniasis. Ann Inst Pasteur Immunol. 1987 Sep-Oct;138(5):781–786. doi: 10.1016/s0769-2625(87)80038-7. [DOI] [PubMed] [Google Scholar]
  24. Modabber F. Development of vaccines against leishmaniasis. Scand J Infect Dis Suppl. 1990;76:72–78. [PubMed] [Google Scholar]
  25. Morris L., Aebischer T., Handman E., Kelso A. Resistance of BALB/c mice to Leishmania major infection is associated with a decrease in the precursor frequency of antigen-specific CD4+ cells secreting interleukin-4. Int Immunol. 1993 Jul;5(7):761–767. doi: 10.1093/intimm/5.7.761. [DOI] [PubMed] [Google Scholar]
  26. Morris L., Troutt A. B., Handman E., Kelso A. Changes in the precursor frequencies of IL-4 and IFN-gamma secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J Immunol. 1992 Oct 15;149(8):2715–2721. [PubMed] [Google Scholar]
  27. Morris L., Troutt A. B., McLeod K. S., Kelso A., Handman E., Aebischer T. Interleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis. Infect Immun. 1993 Aug;61(8):3459–3465. doi: 10.1128/iai.61.8.3459-3465.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Morrissey J. H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  29. Mougneau E., Altare F., Wakil A. E., Zheng S., Coppola T., Wang Z. E., Waldmann R., Locksley R. M., Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science. 1995 Apr 28;268(5210):563–566. doi: 10.1126/science.7725103. [DOI] [PubMed] [Google Scholar]
  30. Murray P. J., Spithill T. W., Handman E. The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen. J Immunol. 1989 Dec 15;143(12):4221–4226. [PubMed] [Google Scholar]
  31. Murray P. J., Spithill T. W. Variants of a Leishmania surface antigen derived from a multigenic family. J Biol Chem. 1991 Dec 25;266(36):24477–24484. [PubMed] [Google Scholar]
  32. Olliaro P. L., Bryceson A. D. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today. 1993 Sep;9(9):323–328. doi: 10.1016/0169-4758(93)90231-4. [DOI] [PubMed] [Google Scholar]
  33. Peters B. S., Fish D., Golden R., Evans D. A., Bryceson A. D., Pinching A. J. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med. 1990 Nov;77(283):1101–1111. doi: 10.1093/qjmed/77.2.1101. [DOI] [PubMed] [Google Scholar]
  34. Playfair J. H., Blackwell J. M., Miller H. R. Modern vaccines. Parasitic diseases. Lancet. 1990 May 26;335(8700):1263–1266. doi: 10.1016/0140-6736(90)91316-3. [DOI] [PubMed] [Google Scholar]
  35. Rachamim N., Jaffe C. L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol. 1993 Mar 15;150(6):2322–2331. [PubMed] [Google Scholar]
  36. Russell D. G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol. 1988 Feb 15;140(4):1274–1279. [PubMed] [Google Scholar]
  37. SAGHER F., VERBI S., ZUCKERMAN A. Immunity to reinfection following recovery from cutaneous leishmaniasis (oriental sore). J Invest Dermatol. 1955 Apr;24(4):417–421. doi: 10.1038/jid.1955.56. [DOI] [PubMed] [Google Scholar]
  38. Scott P., Natovitz P., Coffman R. L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 1988 Nov 1;168(5):1675–1684. doi: 10.1084/jem.168.5.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol. 1987 Jul 1;139(1):221–227. [PubMed] [Google Scholar]
  40. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J Immunol. 1987 Nov 1;139(9):3118–3125. [PubMed] [Google Scholar]
  41. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  42. Snapper C. M., Paul W. E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987 May 22;236(4804):944–947. doi: 10.1126/science.3107127. [DOI] [PubMed] [Google Scholar]
  43. Symons F. M., Murray P. J., Ji H., Simpson R. J., Osborn A. H., Cappai R., Handman E. Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species. Mol Biochem Parasitol. 1994 Sep;67(1):103–113. doi: 10.1016/0166-6851(94)90100-7. [DOI] [PubMed] [Google Scholar]
  44. Titus R. G., Marchand M., Boon T., Louis J. A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985 Sep;7(5):545–555. doi: 10.1111/j.1365-3024.1985.tb00098.x. [DOI] [PubMed] [Google Scholar]
  45. Xu D., McSorley S. J., Chatfield S. N., Dougan G., Liew F. Y. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology. 1995 May;85(1):1–7. [PMC free article] [PubMed] [Google Scholar]
  46. Yang D. M., Rogers M. V., Liew F. Y. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology. 1991 Jan;72(1):3–9. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES